International warfarin genotype-guided dosing algorithms in the Turkish population and their preventive effects on major and life-threatening hemorrhagic events

Basit Öğe Kaydı
dc.authoridPolimanti, Renato -- 0000-0003-0745-6046; Bozkurt, Mehmet -- 0000-0002-8325-5249
dc.contributor.authorKaraca, Şefayet
dc.contributor.authorBozkurt, Nujen Çolak
dc.contributor.authorCesuroğlu, Tomris
dc.contributor.authorKaraca, Mehmet
dc.contributor.authorBozkurt, Mehmet
dc.contributor.authorEskioğlu, Erdal
dc.contributor.authorPolimanti, Renato
dc.date.accessioned13.07.201910:50:10
dc.date.accessioned2019-07-29T19:28:58Z
dc.date.available13.07.201910:50:10
dc.date.available2019-07-29T19:28:58Z
dc.date.issued2015
dc.departmentSağlık Bilimleri Fakültesi
dc.description.abstractTo determine the accuracy of international warfarin pharmacogenetic algorithms developed on large multiethnic cohorts (comprising more than 1000 subjects) to predict therapeutic warfarin doses in Turkish patients. Materials & methods: We investigated two Turkish warfarin-treated cohorts: patients with no history of hemorrhagic or thromboembolic event and patients with major and life-threatening hemorrhagic events. Results: International pharmacogenetic algorithms showed good performances in predicting the therapeutic dose of patients with no history of bleedings, but they did not significantly detect the incorrect warfarin dose of patients with major and life-threatening hemorrhagic events. Conclusion: Although genetic information can predict the therapeutic warfarin dose, the accuracy of the international pharmacogenetic algorithms is not sufficient to be used for warfarin screening in Turkish patients.
dc.description.sponsorshipTurkish Society of Internal Medicine
dc.description.sponsorshipThis research was funded by the Research Projects Fund of Turkish Society of Internal Medicine. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
dc.identifier.doi10.2217/PGS.15.58
dc.identifier.endpage1118en_US
dc.identifier.issn1462-2416
dc.identifier.issn1744-8042
dc.identifier.issue10en_US
dc.identifier.pmid26216670
dc.identifier.scopusqualityQ3
dc.identifier.startpage1109en_US
dc.identifier.urihttps://doi.org/10.2217/PGS.15.58
dc.identifier.urihttps://hdl.handle.net/20.500.12451/6109
dc.identifier.volume16en_US
dc.identifier.wosWOS:000361140600008
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherFuture Medicine LTD
dc.relation.ispartofPharmacogenomics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectDrug Response
dc.subjectEthnicity
dc.subjectPharmacogenetic Algorithms
dc.subjectTurkey
dc.subjectValidation Study
dc.titleInternational warfarin genotype-guided dosing algorithms in the Turkish population and their preventive effects on major and life-threatening hemorrhagic events
dc.typeArticle

Dosyalar

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu